Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

ClinicalTrials.gov ID: NCT00003647

Public ClinicalTrials.gov record NCT00003647. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without immunotherapy in treating patients who have stage III or stage IV melanoma.

Study identification

NCT ID
NCT00003647
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Vical
Industry
Enrollment
Not listed

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Not listed
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 1998 (Type not available)
Primary completion
Not listed
Completion
Sep 2002 (Actual)
Last update posted
Jul 25, 2008

1998 – 2002

United States locations

U.S. sites
44
U.S. states
29
U.S. cities
42
Facility City State ZIP Site status
University of Arkansas for Medical Sciences Little Rock Arkansas 72205 —
Comprehensive Blood and Cancer Center Bakersfield California 93309 —
Scripps Memorial Hospitals-Stevens Cancer Center - Encinitas Encinitas California 92023 —
Kaiser Permanente-Southern California Permanente Medical Group San Diego California 92120 —
Yale Comprehensive Cancer Center New Haven Connecticut 06520-8028 —
Washington Cancer Institute Washington D.C. District of Columbia 20010 —
Mount Sinai Comprehensive Cancer Center Miami Beach Florida 33140 —
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612-9497 —
Georgia Cancer Specialists Decatur Georgia 30033 —
Georgia Cancer Specialists, P.C. East Point Georgia 30344 —
St. Francis Medical Center Honolulu Hawaii 96817 —
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago Illinois 60611-3013 —
Lutheran General Hospital Park Ridge Illinois 60068 —
Cancer Care Center for Southern Indiana Bloomington Indiana 47403 —
Cancer Care Center New Albany Indiana 47150 —
Oncology and Hematology Associates Westwood Kansas 66205 —
Lucille Parker Markey Cancer Center, University of Kentucky Lexington Kentucky 40536-0093 —
Louisiana State University School of Medicine New Orleans Louisiana 70112-2822 —
Franklin Square Hospital Center Baltimore Maryland 21237 —
Providence Hospital Cancer Center Southfield Michigan 48075 —
Virginia Piper Cancer Institute Minneapolis Minnesota 55407 —
North Memorial Health Care Robbinsdale Minnesota 55422 —
Mayo Clinic Cancer Center Rochester Minnesota 55905 —
Park Nicollet Clinic Saint Louis Park Minnesota 55416 —
St. Louis University Health Sciences Center St Louis Missouri 63110-0250 —
Missouri Baptist Cancer Center St Louis Missouri 63131 —
Billings Interhospital Oncology Project Billings Montana 59101 —
Bergan Mercy Medical Center Omaha Nebraska 68124 —
Norris Cotton Cancer Center Lebanon New Hampshire 03756-0002 —
HemOnCare, P.C. Brooklyn New York 11235 —
Arena Oncology Associates Great Neck New York 11021 —
Beth Israel Medical Center New York New York 10003 —
Mount Sinai School of Medicine New York New York 10029 —
Comprehensive Cancer Center at Wake Forest University Winston-Salem North Carolina 27157-1082 —
Mid Dakota Clinic, P.C. Bismarck North Dakota 58501 —
Mid-Ohio Oncology/Hematology, Inc. Columbus Ohio 43222 —
Toledo Clinic, Inc. Toledo Ohio 43623 —
University of Pennsylvania Cancer Center Philadelphia Pennsylvania 19104-4283 —
Cancer Centers of the Carolinas Greenville South Carolina 29605 —
Huntsman Cancer Institute Salt Lake City Utah 84112 —
Danville Hematology and Oncology, Inc. Danville Virginia 24541 —
Cancer Treatment Centers of America in Hampton Roads Portsmouth Virginia 23704 —
Seattle Cancer Care Alliance Seattle Washington 98109 —
Medical College of Wisconsin Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003647, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 25, 2008 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00003647 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →